^
    9ms
    Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) (clinicaltrials.gov)
    P2, N=15, Recruiting, Kintara Therapeutics, Inc. | Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2024 --> Dec 2024
    Enrollment open • Trial primary completion date • Surgery • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    REM-001 therapy
    almost2years
    Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) (clinicaltrials.gov)
    P2, N=15, Not yet recruiting, Kintara Therapeutics, Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Initiation date: Sep 2022 --> Jul 2023 | Trial primary completion date: Aug 2023 --> Jul 2024
    Trial completion date • Trial initiation date • Trial primary completion date • Surgery • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    REM-001 therapy
    2years
    Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) (clinicaltrials.gov)
    P2, N=15, Not yet recruiting, Kintara Therapeutics, Inc. | Initiation date: Jun 2022 --> Sep 2022
    Trial initiation date • Surgery • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    REM-001 therapy
    over2years
    Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) (clinicaltrials.gov)
    P2, N=15, Not yet recruiting, Kintara Therapeutics, Inc.
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    REM-001 therapy